Biocept

Biocept Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Biocept (BIOCQ) as of Nov 11, 2026 is 41.42 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was -130.67 % — a change of -131.70% (higher).

Cash Conversion

41.42 %

YoY

-131.70%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Biocept is 2022 41.42 % . Cash Conversion Rate (OCF/Net Income) of Biocept was 2021 -130.67 % . It decreases by -131.70% higher compared to the previous year.

The Biocept Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2015
89.38 USD
Jan 1, 2016
85.33 USD
Jan 1, 2017
90.93 USD
Jan 1, 2018
88.69 USD
Jan 1, 2019
91.69 USD
Jan 1, 2020
111.12 USD
Jan 1, 2021
-130.67 USD
Jan 1, 2022
41.42 USD
The Biocept Cash Conversion history
YEARCash ConversionYoY
41.42 %-131.70%
-130.67 %-217.59%
111.12 %+21.19%
91.69 %+3.38%
88.69 %-2.46%
90.93 %+6.57%
85.33 %-4.54%
89.38 %-2.71%
91.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocept Stock analysis

What does Biocept do? Biocept, Inc. generates revenue through its oncology laboratory services, focusing on the detection of rare cells such as circulating tumor cells. The company markets its CNSide brand, which includes a suite of cellular and molecular technologies for central nervous system disease management. Its diagnostic assays, such as cell capture and enumeration, immunocytochemistry, FISH, and NGS, are commercialized for detecting various carcinomas and melanoma in blood and cerebrospinal fluid. Medical professionals and healthcare providers purchase these services to aid in patient diagnosis and treatment management. The CNSide product suite is designed for use in cerebrospinal fluid analysis, targeting solid tumor patients. Biocept's assays are specifically tailored for identifying rare tumor cells and cell-free tumor DNA, supporting clinical decision-making. The company's focus on solid tumors and CNS disease management positions it within the diagnostic laboratory services market, where healthcare institutions seek advanced tools for oncology care. Biocept's commercialized assays include cell capture, enumeration, immunocytochemistry, FISH, and NGS, all under the CNSide brand. These products are sold to medical professionals who require precise diagnostic tools for central nervous system disease management. The company's offerings are targeted at healthcare providers managing patients with solid tumors, particularly those requiring CSF analysis for disease monitoring and treatment planning. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

Cash Conversion Rate (OCF/Net Income) of Biocept is 41.42 % in 2022.

Cash Conversion Rate (OCF/Net Income) of Biocept changed from -130.67 % to 41.42 %, representing a -131.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Biocept since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Biocept with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biocept

All Key Metrics — Biocept